A simplified prognostic index for chronic lymphocytic leukemia treated with ibrutinib: Results from a multicenter retrospective cohort study

Leuk Res. 2020 Feb:89:106302. doi: 10.1016/j.leukres.2020.106302. Epub 2020 Jan 21.

Authors

Affiliations

¹ Oregon Health and Science University, 3181 SW Sam Jackson Pkwy, Portland, 97239, United States. Electronic address: gordo422@umn.edu.
² Oregon Health and Science University, 3181 SW Sam Jackson Pkwy, Portland, 97239, United States.
³ Oregon Health and Science University, 3181 SW Sam Jackson Pkwy, Portland, 97239, United States. Electronic address: danilov@ohsu.edu.

PMID: 31982152
DOI: 10.1016/j.leukres.2020.106302

No abstract available

Keywords: Chronic lymphocytic leukemia; Ibrutinib; Prognostic index.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adenine / analogs & derivatives
Area Under Curve
Female
Humans
Immunoglobulin Heavy Chains / genetics
In Situ Hybridization, Fluorescence
Incidence
Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy
Leukemia, Lymphocytic, Chronic, B-Cell / epidemiology*
Leukemia, Lymphocytic, Chronic, B-Cell / mortality
Male
Multicenter Studies as Topic
Piperidines
Prognosis
Protein Kinase Inhibitors / administration & dosage
Protein Kinase Inhibitors / adverse effects
Protein Kinase Inhibitors / therapeutic use
Pyrazoles / administration & dosage
Pyrazoles / adverse effects
Pyrazoles / therapeutic use
Pyrimidines / administration & dosage
Pyrimidines / adverse effects
Pyrimidines / therapeutic use
Retrospective Studies

Substances

Immunoglobulin Heavy Chains
Piperidines
Protein Kinase Inhibitors
Pyrazoles
Pyrimidines
ibrutinib
Adenine